Kiniksa Pharmaceuticals Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Kiniksa Pharmaceuticals stock.
View analyst ratings for Kiniksa Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Kiniksa Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kiniksa Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Kiniksa Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Kiniksa Pharmaceuticals.

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) posted its earnings results on Tuesday, August, 3rd. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.69) by $0.08.
View Kiniksa Pharmaceuticals' earnings history.

Kiniksa Pharmaceuticals' stock was trading at $16.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KNSA stock has decreased by 18.6% and is now trading at $13.11.
View which stocks have been most impacted by COVID-19.

2 equities research analysts have issued 1-year price objectives for Kiniksa Pharmaceuticals' stock. Their forecasts range from $24.00 to $24.00. On average, they expect Kiniksa Pharmaceuticals' share price to reach $24.00 in the next twelve months. This suggests a possible upside of 83.1% from the stock's current price.
View analysts' price targets for Kiniksa Pharmaceuticals or view top-rated stocks among Wall Street analysts.

1 employees have rated Kiniksa Pharmaceuticals CEO Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among Kiniksa Pharmaceuticals' employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Kiniksa Pharmaceuticals include Cassava Sciences (SAVA), TG Therapeutics (TGTX), Cerevel Therapeutics (CERE), Emergent BioSolutions (EBS), ACADIA Pharmaceuticals (ACAD), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Verve Therapeutics (VERV), Dicerna Pharmaceuticals (DRNA), Nektar Therapeutics (NKTR), Cryoport (CYRX), Intra-Cellular Therapies (ITCI), Taro Pharmaceutical Industries (TARO), Agios Pharmaceuticals (AGIO) and PTC Therapeutics (PTCT).
View all of KNSA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).

(KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

Kiniksa Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (1.08%), Alliancebernstein L.P. (0.05%), Vigilare Wealth Management (0.03%), Russell Investments Group Ltd. (0.02%) and Cutler Group LP (0.00%). Company insiders that own Kiniksa Pharmaceuticals stock include John F Paolini, Sanj K Patel and Thomas W Beetham.
View institutional ownership trends for Kiniksa Pharmaceuticals.

KNSA stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP, and Russell Investments Group Ltd.. Company insiders that have sold Kiniksa Pharmaceuticals company stock in the last year include Sanj K Patel, and Thomas W Beetham.
View insider buying and selling activity for Kiniksa Pharmaceuticals or view top insider-selling stocks.

KNSA stock was purchased by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Alliancebernstein L.P., and Vigilare Wealth Management.
View insider buying and selling activity for Kiniksa Pharmaceuticals or or view top insider-buying stocks.

Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KNSA stock can currently be purchased for approximately $13.11.

Kiniksa Pharmaceuticals has a market capitalization of $894.50 million. The company earns $-161,380,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis.

Kiniksa Pharmaceuticals employs 168 workers across the globe.

The official website for Kiniksa Pharmaceuticals is www.kiniksa.com.

Kiniksa Pharmaceuticals is headquartered at CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11.

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 44-80-8189-6257 or via email at [email protected]